Immune System News and Research

RSS

MV vaccine prevents TB in people with HIV infection

Results from clinical trials conducted in Tanzania show that a new vaccine against tuberculosis, Mycobacterium vaccae (MV), is effective in preventing tuberculosis in people with HIV infection. Findings from the trials, which were conducted by investigators from Dartmouth Medical School in the United States, will be published in the next issue of AIDS, the leading journal in the field of HIV and AIDS research. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

3 Feb 2010

Scientists are getting closer to prove how cholesterol causes heart disease

By considering molecular-level events on a broader scale, researchers now have a clearer, if more complicated, picture of how one class of immune cells goes wrong when loaded with cholesterol. The findings reported in the February 3rd issue of Cell Metabolism, a Cell Press publication, show that, when it comes to the development of atherosclerosis and heart disease, it's not about any one bad actor-it's about a network gone awry.

3 Feb 2010

PATH to pay FDA $480,000 to speed creation of pneumococcal vaccine for developing world

The FDA on Monday said it's entering into a collaboration with the nonprofit group PATH "to speed creation of a pneumococcal vaccine for children in developing nations," United Press International reports (2/1).

3 Feb 2010

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Compugen Ltd. announced today the discovery and experimental validation of CGEN-15001 for the treatment of autoimmune disorders.

2 Feb 2010

Xiaflex receives FDA approval for treatment of Dupuytren's contracture

The U.S. Food and Drug Administration today approved Xiaflex (collagenase clostridium histolyticum) as the first drug to treat a progressive hand disease known as Dupuytren's contracture, which can affect a person's ability to straighten and properly use their fingers.

2 Feb 2010

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

ZymoGenetics, Inc., today announced the publication of pooled safety and immunogenicity observations from eight clinical trials of RECOTHROM in the February issue of the Journal of the American College of Surgeons. The authors concluded that RECOTHROM is a well-tolerated topical hemostatic agent in numerous surgical settings and has a low rate of anti-product antibody formation. In the pooled data from all trials, less than one percent of treated patients developed product-specific antibodies. None of the antibodies neutralized native coagulation proteins.

2 Feb 2010

Cytheris broadens patent protection for recombinant human interleukin-7

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO’s official communication that the Company’s application has successfully completed examination and that a patent will be issued.

2 Feb 2010

Pandemic H1N1 influenza of swine origin has distinct means of transmission from seasonal flu

Current research suggests that pandemic H1N1 influenza of swine origin has distinct means of transmission from the seasonal flu, yet does not result in the pathogenic severity of avian flu viruses.

2 Feb 2010

Studies suggest potential therapeutic targets for food poisoning, TB and autoimmune diseases

Researchers at National Jewish Health have discovered how the virulent food-borne bacteria Listeria monocytogenes induces infected immune cells to sabotage their own defensive response.

2 Feb 2010

FDA and PATH collaborate to advance pneumococcal vaccine development for children

The U.S. Food and Drug Administration (FDA) today announced a collaboration with PATH to advance development of a vaccine to protect children against diseases caused by Streptococcus pneumoniae (pneumococcus), especially pneumonia.

2 Feb 2010

FDA approves neurostimulation treatment for heart failure

The FDA recently approved the first study of neurostimulation as a treatment for heart failure, a chronic disease that affects nearly six million Americans and is the leading cause of hospitalization in America.

2 Feb 2010

Study could help in developing therapeutic strategies for Chikungunya virus infection

A study published online on February 1 in the Journal of Experimental Medicine (www.jem.org) shows that antiviral proteins called type I interferons (IFNs) are needed to fend off infection with an exotic mosquito-borne virus called Chikungunya virus.

2 Feb 2010

Experimental vaccine reduced TB rate among HIV-positive people in Tanzania, Study finds

An experimental vaccine was found to reduce the rate of tuberculosis infections in patients living with HIV, "the first time a shot has been shown to reduce cases of the most common AIDS-related cause of death in poor nations," Bloomberg reports (Bennett, 1/29). Tuberculosis accounts for up to one-third of AIDS deaths worldwide, CBC News reports.

1 Feb 2010

Patients with rare autoimmune disease produce antibodies that disarm immune proteins

Two studies published online on February 1 in the Journal of Experimental Medicine (www.jem.org) reveal that patients with a rare autoimmune disease produce antibodies that attack microbe-fighting immune proteins called cytokines.

1 Feb 2010

Ipsen reports consolidated group sales of €1,032.8M for 2009

Ipsen reported today its sales for the fourth quarter and full year 2009.

1 Feb 2010

Study indicates dogs make excellent models for studying human genetic disorders

In the new Swedish-Finnish study, published in Nature Genetics, the researchers identified five loci that predispose to an SLE-related disease in Nova Scotia duck tolling retrievers.

31 Jan 2010

Enzo Biochem generating more than $100M in revenues annually

Enzo Biochem, Inc. is well positioned to benefit from the results of its transformation involving acquisitions, new managements at each of its major subsidiaries and a heightened focus on new life science, diagnostic and therapeutic products, Barry Weiner, President, told the annual meeting of shareholders today.

30 Jan 2010

Immune System News and Research

MV vaccine prevents TB in people with HIV infection

Scientists are getting closer to prove how cholesterol causes heart disease

PATH to pay FDA $480,000 to speed creation of pneumococcal vaccine for developing world

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Xiaflex receives FDA approval for treatment of Dupuytren's contracture

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

Cytheris broadens patent protection for recombinant human interleukin-7

Pandemic H1N1 influenza of swine origin has distinct means of transmission from seasonal flu

Studies suggest potential therapeutic targets for food poisoning, TB and autoimmune diseases

FDA and PATH collaborate to advance pneumococcal vaccine development for children

FDA approves neurostimulation treatment for heart failure

Study could help in developing therapeutic strategies for Chikungunya virus infection

Experimental vaccine reduced TB rate among HIV-positive people in Tanzania, Study finds

Patients with rare autoimmune disease produce antibodies that disarm immune proteins

Ipsen reports consolidated group sales of €1,032.8M for 2009

Study indicates dogs make excellent models for studying human genetic disorders

Enzo Biochem generating more than $100M in revenues annually

USPTO allows claims to Rosetta Genomics' two microRNA related patent applications

Tips to prevent potential health problems in the future

New vaccine effective in preventing TB in HIV patients

Immunology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News